CY1120413T1 - Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου - Google Patents

Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Info

Publication number
CY1120413T1
CY1120413T1 CY20181100343T CY181100343T CY1120413T1 CY 1120413 T1 CY1120413 T1 CY 1120413T1 CY 20181100343 T CY20181100343 T CY 20181100343T CY 181100343 T CY181100343 T CY 181100343T CY 1120413 T1 CY1120413 T1 CY 1120413T1
Authority
CY
Cyprus
Prior art keywords
beta
humanized antibodies
proteinological
specially
amyloid peptide
Prior art date
Application number
CY20181100343T
Other languages
English (en)
Inventor
Nicolas Baurin
Francis Blanche
Béatrice Cameron
Marc Duchesne
Vincent Mikol
Souad Naimi
Laurent Pradier
Yi Shi
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120413(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1120413T1 publication Critical patent/CY1120413T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Abstract

Η παρούσα αίτηση σχετίζεται με ειδικά εξανθρωπισμένα αντισώματα στην πρωτοϊνιδιακή μορφή του βήτα-αμυλοειδούς πεπτιδίου, καθώς και με την χρήση αυτών των αντισωμάτων στο πεδίο της νόσου Alzheimer.
CY20181100343T 2009-05-12 2018-03-27 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου CY1120413T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0953133A FR2945538B1 (fr) 2009-05-12 2009-05-12 Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP10728743.5A EP2430049B1 (fr) 2009-05-12 2010-05-11 Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Publications (1)

Publication Number Publication Date
CY1120413T1 true CY1120413T1 (el) 2019-07-10

Family

ID=41591699

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100622T CY1116842T1 (el) 2009-05-12 2015-07-14 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY20181100343T CY1120413T1 (el) 2009-05-12 2018-03-27 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100622T CY1116842T1 (el) 2009-05-12 2015-07-14 Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου

Country Status (42)

Country Link
US (4) US8614299B2 (el)
EP (3) EP3050898B1 (el)
JP (2) JP2012526541A (el)
KR (1) KR101783058B1 (el)
CN (1) CN102459336B (el)
AR (1) AR076670A1 (el)
AU (1) AU2010247215B2 (el)
BR (1) BRPI1012853B1 (el)
CA (1) CA2761665A1 (el)
CL (1) CL2011002831A1 (el)
CO (1) CO6460745A2 (el)
CR (1) CR20110585A (el)
CY (2) CY1116842T1 (el)
DK (2) DK2977385T3 (el)
EA (1) EA028357B1 (el)
EC (1) ECSP11011452A (el)
ES (2) ES2542757T3 (el)
FR (1) FR2945538B1 (el)
GT (1) GT201100283A (el)
HK (1) HK1167152A1 (el)
HR (3) HRP20150776T1 (el)
HU (1) HUE036737T2 (el)
IL (1) IL216237B (el)
LT (1) LT2977385T (el)
MA (1) MA33350B1 (el)
MX (1) MX2011012060A (el)
MY (1) MY159398A (el)
NI (1) NI201100195A (el)
NZ (1) NZ596540A (el)
PE (1) PE20120906A1 (el)
PL (2) PL2977385T3 (el)
PT (2) PT2977385T (el)
RS (1) RS54122B1 (el)
SG (1) SG176155A1 (el)
SI (2) SI2430049T1 (el)
SV (1) SV2011004058A (el)
TN (1) TN2011000571A1 (el)
TW (2) TWI583791B (el)
UA (1) UA107574C2 (el)
UY (1) UY32633A (el)
WO (1) WO2010130946A1 (el)
ZA (1) ZA201108301B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
KR102218494B1 (ko) * 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
PL3280441T3 (pl) 2015-04-07 2022-02-21 Alector Llc Przeciwciała przeciwko sortilinie i sposoby ich stosowania
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
SG10201912085WA (en) 2015-06-12 2020-02-27 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
CN108137702B (zh) 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
AU2016334051B2 (en) 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
CN116003596A (zh) 2015-10-29 2023-04-25 艾利妥 抗siglec-9抗体及其使用方法
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CR20190486A (es) 2017-08-03 2020-02-10 Alector Llc Anti-cd33 antibodies and methods of use thereof
SI3601358T1 (sl) 2017-08-03 2023-10-30 Alector Llc Protitelesa ANTI-TREM2 in načini njihove uporabe
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112020024919A2 (pt) 2018-06-08 2021-03-09 Alector Llc Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
WO2020014617A1 (en) 2018-07-13 2020-01-16 Alector Llc Anti-sortilin antibodies and methods of use thereof
EP3830123A1 (en) 2018-07-27 2021-06-09 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
TW202016307A (zh) 2018-08-31 2020-05-01 美商阿列克特有限責任公司 抗cd33 抗體及其使用方法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
CN114245807A (zh) 2019-06-25 2022-03-25 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
US20220356233A1 (en) * 2019-08-20 2022-11-10 The Curators Of The University Of Missouri Amyloid-beta antibodies
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
PE20231105A1 (es) 2020-08-25 2023-07-19 Gilead Sciences Inc Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US6943240B2 (en) * 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
PL1674111T3 (pl) * 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
US7927594B2 (en) * 2004-07-30 2011-04-19 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
JP2009533653A (ja) * 2006-03-22 2009-09-17 ギロス パテント アーべー プレックス（ｐｌｅｘ）方法
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2436696T1 (sl) * 2007-01-05 2017-10-30 University Of Zurich Anti-beta-amiloidno protitelo in načini njegove uporabe
NZ597466A (en) * 2007-03-01 2013-08-30 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
CN111909273B (zh) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
BRPI0915667B8 (pt) * 2008-07-08 2021-05-25 Geneuro Sa ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, ligante, composição farmacêutica, método de detecção do antiligante em uma amostra biológica e kit de imunoensaio para detecção do antiligante em uma amostra biológica
CA2754906C (en) * 2009-03-10 2021-02-09 Baylor Research Institute Antigen presenting cell targeted fusion proteins comprising a linker for increased stability
CN105884903B (zh) * 2009-03-10 2019-12-06 贝勒研究院 靶向抗原呈递细胞的疫苗
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Also Published As

Publication number Publication date
PT2430049E (pt) 2015-09-01
ES2542757T3 (es) 2015-08-11
US9382312B2 (en) 2016-07-05
EP3050898A1 (fr) 2016-08-03
ECSP11011452A (es) 2011-12-30
EP2430049B1 (fr) 2015-04-15
CO6460745A2 (es) 2012-06-15
EP3050898B1 (fr) 2018-08-15
PE20120906A1 (es) 2012-08-08
CY1116842T1 (el) 2017-03-15
US20160368977A1 (en) 2016-12-22
JP2016028591A (ja) 2016-03-03
DK2977385T3 (en) 2018-04-16
AR076670A1 (es) 2011-06-29
US20140105890A1 (en) 2014-04-17
PL2430049T3 (pl) 2015-09-30
CN102459336B (zh) 2016-04-20
CR20110585A (es) 2011-12-07
KR20120096950A (ko) 2012-08-31
HRP20180516T1 (hr) 2018-05-04
AU2010247215A1 (en) 2011-12-15
RS54122B1 (en) 2015-12-31
SI2977385T1 (en) 2018-05-31
MY159398A (en) 2016-12-30
HRP20181985T1 (hr) 2019-01-25
TN2011000571A1 (fr) 2013-05-24
KR101783058B1 (ko) 2017-09-28
TW201641690A (zh) 2016-12-01
TWI583791B (zh) 2017-05-21
GT201100283A (es) 2013-11-07
HUE036737T2 (hu) 2018-07-30
BRPI1012853B1 (pt) 2021-08-24
US10112991B2 (en) 2018-10-30
FR2945538A1 (fr) 2010-11-19
ZA201108301B (en) 2013-01-30
NI201100195A (es) 2012-02-01
US8614299B2 (en) 2013-12-24
TW201100102A (en) 2011-01-01
UY32633A (es) 2010-12-31
LT2977385T (lt) 2018-04-10
SI2430049T1 (sl) 2015-08-31
EP2977385A1 (fr) 2016-01-27
EP2977385B1 (fr) 2017-12-27
HK1167152A1 (en) 2012-11-23
MA33350B1 (fr) 2012-06-01
SG176155A1 (en) 2011-12-29
UA107574C2 (ru) 2015-01-26
FR2945538B1 (fr) 2014-12-26
BRPI1012853A2 (pt) 2018-06-19
US20190119365A1 (en) 2019-04-25
PT2977385T (pt) 2018-04-03
TWI542360B (zh) 2016-07-21
EA201171388A1 (ru) 2012-05-30
CL2011002831A1 (es) 2012-05-11
US20120177639A1 (en) 2012-07-12
MX2011012060A (es) 2012-04-30
IL216237A0 (en) 2012-01-31
AU2010247215B2 (en) 2015-08-20
ES2664409T3 (es) 2018-04-19
EA028357B1 (ru) 2017-11-30
DK2430049T3 (en) 2015-07-20
NZ596540A (en) 2013-05-31
JP6310895B2 (ja) 2018-04-11
IL216237B (en) 2018-05-31
PL2977385T3 (pl) 2018-06-29
WO2010130946A1 (fr) 2010-11-18
CN102459336A (zh) 2012-05-16
JP2012526541A (ja) 2012-11-01
EP2430049A1 (fr) 2012-03-21
SV2011004058A (es) 2012-06-06
CA2761665A1 (fr) 2010-11-18
HRP20150776T1 (hr) 2015-08-28

Similar Documents

Publication Publication Date Title
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118014T1 (el) Aνti-il-23 αντισωματα
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
TR201910721T4 (tr) İnsan OX40'a yönelik spesifisiteye sahip olan antikor molekülleri.
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA111818C2 (uk) Антитіло проти csf-1r
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
EA201390467A1 (ru) Композиции антител и способы применения
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EA200970816A1 (ru) Новая лекарственная форма
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
CY1116623T1 (el) Συνθεσεις και μεθοδοι για αντισωματα κατα της πρωτεϊνης c5 συμπληρωματος
UA111322C2 (uk) Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування
TH128722B (th) ฮิวมาไนซ์แอนติบอดีที่จำเพาะต่อรูปโปรโตไฟบริลลาร์ของบีตา-อมัยลอยด์เพพไทด์